Stock Price
P/E Ratio
Volume Traded Today
Dividend
52 Week High/low
American Well Corp Market Cap
The American Well Corp (AMWL) share price is expected to increase by 86.75% over the next year. This is based on calculating the average 12-month share price estimate provided by 0 stock analysts who have covered AMWL. Price targets range from $8 at the low end to $66 at the high end. The current analyst consensus for AMWL is a sell. Please note analyst price targets are not guaranteed and could be missed completely.
About 0 Wall Street analysts have assignedAMWL 0 buy ratings, 0 hold ratings, and 0 sell ratings. This means that analysts expect American Well Corp to sell. Keep in mind that these ratings are typically refreshed every quarter, underscoring the importance of conducting your own research on AMWL. Don't forget to include both technical and fundamental analysis, as well as staying informed on news that could influence these ratings, in your due diligence.
These are the latest 20 analyst ratings of AMWL.
|
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
|---|---|---|---|---|
| Ryan MacDonald Needham | Hold | Reiterates | Sep 24, 2024 | |
| Stan Berenshteyn Wells Fargo | Equal-Weight | $15 | Maintains | Aug 6, 2024 |
| Ryan MacDonald Needham | Hold | Reiterates | Aug 1, 2024 | |
| Kevin Caliendo UBS | Neutral | $0.6 | Maintains | May 23, 2024 |
| Ryan MacDonald Needham | Hold | Reiterates | May 2, 2024 | |
| Craig Hettenbach Morgan Stanley | Equal-Weight | $1 | Maintains | Apr 15, 2024 |
| Craig Hettenbach Morgan Stanley | Equal-Weight | $1.75 | Maintains | Nov 2, 2023 |
| Craig Hettenbach Morgan Stanley | Equal-Weight | $2.5 | Downgrade | Aug 3, 2023 |
| Jonathan Yong Credit Suisse | Neutral | $3.5 | Maintains | May 4, 2023 |
| Charles Rhyee TD Cowen | Market Perform | $2.5 | Downgrade | Mar 23, 2023 |
| Jack Wallace Guggenheim | Buy | $5 | Reiterates | Mar 15, 2023 |
| Craig Hettenbach Morgan Stanley | Overweight | $5 | Maintains | Mar 13, 2023 |
| Jessica Tassan Piper Sandler | Neutral | $3.5 | Downgrade | Feb 27, 2023 |
| Jonathan Yong Credit Suisse | Neutral | $4 | Maintains | Feb 23, 2023 |
| Ryan MacDonald Needham | Hold | Maintains | Feb 23, 2023 | |
| Ricky Goldwasser Morgan Stanley | Overweight | $6 | Maintains | Jan 6, 2023 |
| Allen Lutz B of A Securities | Buy | $4.2 | Upgrade | Jan 4, 2023 |
| Jessica Tassan Piper Sandler | Overweight | $5 | Maintains | Sep 7, 2022 |
| Jailendra Singh Truist Securities | Hold | $5 | Initiates | Sep 7, 2022 |
| Sean Wieland Piper Sandler | Overweight | $6 | Maintains | Jun 23, 2022 |
When did it IPO
2020
Staff Count
1,104
Country
United States
Sector/Industry
Healthcare/Health Information Services
CEO
Dr. Ido Schoenberg M.D.
Market Cap
$138.7M
In 2023, AMWL generated $259.0M in revenue, which was a decrease of -6.55% from the previous year. This can be seen as a signal that AMWL's business is declining, and its share price could be worth less in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2020
Revenue From 2021
Revenue From 2022
Revenue From 2023
Thu, 22 Aug 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - Amwell (NYSE: AMWL) will participate in multiple investor conferences in September, highlighting its position in hybrid care enablement.
Why It Matters - Amwell's participation in investor conferences signals potential growth opportunities and increased visibility, which could influence stock performance and investor sentiment.
Mon, 05 Aug 2024
Sentiment - NEUTRAL
Source - InvestorPlace
Summary - During the pandemic, telemedicine stocks surged, with Teledoc Health (NYSE: TDOC) rising from $80 to a peak of $288.80 due to increased demand for remote medical care.
Why It Matters - Telemedicine stocks surged during the pandemic due to increased demand. Their performance indicates potential growth opportunities and market resilience, influencing investment strategies.
Wed, 31 Jul 2024
Sentiment - POSITIVE
Source - PYMNTS
Summary - Amwell reported Q2 revenue of $62.8 million, exceeding guidance. Subscription revenue was $27.5 million, and visit revenue was $28.7 million. The net loss decreased to $49.9 million.
Why It Matters - Amwell's Q2 revenue exceeds guidance, indicating growth potential. The reduced net loss suggests improving financial health, which could enhance investor confidence and stock performance.
Wed, 31 Jul 2024
Sentiment - NEUTRAL
Source - Seeking Alpha
Summary - American Well Corporation (NYSE: AMWL) will host its Q2 2024 Earnings Conference Call on July 31, 2024, at 5:00 PM ET, featuring key executives and analysts from various firms.
Why It Matters - The upcoming earnings call for American Well Corporation provides insights into financial performance, strategy, and market positioning, which can influence stock valuation and investor sentiment.
Wed, 31 Jul 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - Amwell (NYSE: AMWL) reported its Q2 2024 financial results for the period ending June 30. Details are available on their investor relations website.
Why It Matters - Amwell's Q2 2024 financial results reveal its growth trajectory, impacting its valuation, investor sentiment, and potential market position in the healthcare SaaS sector.
Wed, 31 Jul 2024
Sentiment - NEGATIVE
Source - Zacks Investment Research
Summary - American Well Corporation (AMWL) reported a quarterly loss of $3.36 per share, beating the Zacks Consensus Estimate of $3.94, and improved from a loss of $4.60 per share a year prior.
Why It Matters - American Well's smaller-than-expected loss indicates improving performance, potentially boosting investor confidence and affecting stock sentiment positively.
The information that Ticker Nerd provides is general in nature as it has been prepared without taking account of your objectives, financial situation or needs. It is not intended as legal, financial or investment advice and should not be construed or relied on as such. Ticker Nerd is for information purposes only. Ticker Nerd is not responsible for any damages or losses that may occur as a result of reliance on this information. Before making any commitment of a legal or financial nature you should seek advice from a qualified and registered legal practitioner or financial or investment adviser. All content, group, messaging, tweets, newsletter, article, and email created by Ticker Nerd is intended for educational and information purposes only, is not financial, investment, legal or tax advice, and is a restatement, summary or extract of other data and research reports that are widely distributed from sources such as, but not limited to, Bloomberg, Market Watch, Wall Street Journal, Google Finance, and Yahoo Finance. Ticker Nerd is not a registered financial, investment, legal or tax advisor and is not liable for any financial loss you may incur acting on any information provided by Ticker Nerd. By registering, you agree not to hold Ticker Nerd liable at any time or under any circumstances for your decisions, actions, or results.
